Clinical trials: Human Cancers
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy or with sintilimab in…
- Trial name
- NCT05718219
- Testing
- SIM0348, SIM0348 + Sintilimab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory…
- Trial name
- NCT06018129
- Testing
- GEN3017
- Where
- 4 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Genmab
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Advanced Malignant Solid Tumor
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer.
- Trial name
- NCT06150183
- Testing
- BNT314
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 41 people
- Sponsor
- BioNTech SE
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Cancer
A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-F16SIP as an anti-cancer therapeutic agent.
- Trial name
- NCT01240720
- Testing
- 131I-F16SIP Radioimmunotherapy (RIT)
- Where
- 6 sites in Italy
- Volunteers
- 65 people
- Sponsor
- Philogen S.p.A.
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Melanoma, Malignant Metastatic Melanoma
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
The primary objectives of this study are: To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. To determine the safety of MEDI-522 ± DTIC in this patient population.
- Trial name
- NCT00066196
- Testing
- MEDI--522, Integrin + Dacarbazine
- Where
- 25 sites in United States
- Volunteers
- 110 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid…
- Trial name
- NCT00361335
- Testing
- Golimumab, Methotrexate
- Where
- 72 sites in United States, Argentina and 13 more
- Volunteers
- 643 people
- Sponsor
- Centocor, Inc.
Infections, Papillomavirus
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
The purpose of this study is to establish the long-term persistence of the immune response and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary study (NCT00541970).
- Trial name
- NCT02100618
- Testing
- Blood sampling
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer, Hematologic Diseases
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy.
- Conditions
- Cancer, Hematologic Diseases, Fever, Neutropenia
- Trial name
- NCT00520325
- Testing
- Intravenous recombinant human mannose binding lectin
- Sponsor
- Enzon Pharmaceuticals, Inc.
B-Cell Non-Hodgkin Lymphoma
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory…
- Trial name
- NCT07658352
- Testing
- HP-002
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shanghai Helioson Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Metastatic Solid Cancer
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ezabenlimab.
- Trial name
- NCT07607678
- Testing
- BI 3819026, Ezabenlimab (BI 754091)
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, Melanoma
IMM60 and Pembrolizumab in Melanoma and NSCLC
The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer.
- Trial name
- NCT05709821
- Testing
- IMM60, Pembrolizumab
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 1 people
- Sponsor
- iOx Therapeutics
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071084
- Testing
- HuMax-CD4
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Genmab
Genital Warts, Anal Cancer
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Trial name
- NCT01651949
- Testing
- 9vHPV Vaccine
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gastrointestinal Stromal Tumor (GIST)
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
The purpose of this study is to evaluate the tumor response of stable disease (SD), partial response (PR), or complete response (CR) [according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1 criteria)]…
- Trial name
- NCT01316263
- Testing
- Olaratumab
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.